BioCryst Pharmaceuticals, Inc. has announced its financial results for the third quarter of 2026, marking a significant achievement in growth and profitability. The company reported total net revenue of $180.3 million, with ORLADEYO net revenue contributing $174.8 million. This performance underscores BioCryst's strong position in the biotechnology sector, particularly in the development of treatments for hereditary angioedema (HAE).

The announcement was made on November 4, 2026, during a conference call where executives discussed the company's recent corporate developments and financial outcomes. Charlie Gayer, President and CEO of BioCryst, emphasized the company's successful launch of ORLADEYO pellets for pediatric patients and the FDA's recent approval for its use in adolescents and adults.

Background

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative medicines for rare diseases, particularly hereditary angioedema. The company trades under the ticker symbol BCRX on the Nasdaq exchange and is classified under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). Recent filings include an 8-K on November 4, 2026, detailing the company's financial results and corporate updates.

What the Filing Says

The filing reveals that BioCryst achieved an operating profit of $53.3 million for Q3 2026, a notable increase from $29.6 million in Q3 2025. The company also reported a net income of $37.9 million, compared to $12.9 million in the same quarter last year. Gayer stated, "In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success." The company maintained its revenue guidance for ORLADEYO at $625 to $645 million for the full year 2026, while increasing its total revenue guidance to between $715 million and $730 million.

Impact

This financial update may significantly affect various stakeholders, including investors, patients, and healthcare providers. The strong performance of ORLADEYO and the company's strategic partnerships, particularly with CareMed as its specialty pharmacy partner, may enhance access to treatment for patients with HAE. Additionally, the announcement reflects positively on the broader biological products industry, as companies focus on innovative treatments for rare diseases.

What's Next

BioCryst plans to continue its focus on pipeline advancements, with expectations to release early clinical data for BCX17725 by the end of 2026 and pivotal results for navenibart in Q3 2027. The filing does not specify any immediate next steps beyond these developments.